A phase I, open-label, dose-escalation study of CAR001 (mRNA-engineered Nb-CAR.BiTE-γδ T cells) in patients with relapsed or refractory solid tumors. This is an ASCO Meeting Abstract from the 2026 ...
The dose escalation of biologic therapy was effective in achieving remission in up to approximately half of patients with inflammatory bowel disease (IBD), with a probability of sustaining the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results